Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose

J Neuroimmunol. 2010 Sep 14;226(1-2):150-7. doi: 10.1016/j.jneuroim.2010.05.038. Epub 2010 Jun 23.


Of 37 multiple sclerosis patients, 19 suboptimal responders were randomized to 375 (n=12) or 250µg (n=7) interferon (IFN)-β-1b. mRNA levels of 23 cytokines, chemokines, and chemokine receptors were quantified by TaqMan low-density array (TLDA) real-time polymerase chain reaction. Better treatment responses or increased IFN-β doses were associated with elevated IL-10 and TGF-β and decreased CXCL10, IL-18, IFN-γ, and TNF-α transcript levels. Adjusting for dose, poor treatment responses resulted in a 4-fold increase in CXCL10 and IFN-γ expression (Mantel-Haenszel RR=3.74, p<0.0001). CXCL10 and IFN-γ mRNA levels were reliable indicators of treatment response. TLDA can be used to tailor IFN-β-1b therapy.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cytokines / blood*
  • Cytokines / classification
  • Cytokines / genetics*
  • Dose-Response Relationship, Drug
  • Female
  • Gene Expression Regulation / drug effects
  • Humans
  • Interferon-beta / pharmacology
  • Interferon-beta / therapeutic use*
  • Longitudinal Studies
  • Male
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*
  • RNA, Messenger / blood*
  • Young Adult


  • Cytokines
  • RNA, Messenger
  • Interferon-beta